These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 20827195

  • 1. Management options for cast nephropathy in multiple myeloma.
    Cockwell P, Hutchison CA.
    Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):550-5. PubMed ID: 20827195
    [Abstract] [Full Text] [Related]

  • 2. Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis.
    Hutchison CA, Heyne N, Airia P, Schindler R, Zickler D, Cook M, Cockwell P, Grima D.
    Nephrol Dial Transplant; 2012 Oct; 27(10):3823-8. PubMed ID: 22273664
    [Abstract] [Full Text] [Related]

  • 3. Treatment by long haemodialysis sessions with high cut-off filters in myeloma cast nephropathy: our experience.
    Borrego-Hinojosa J, Pérez-del Barrio MP, Biechy-Baldan Mdel M, Merino-García E, Sánchez-Perales MC, García-Cortés MJ, Ocaña-Pérez E, Gutiérrez-Rivas P, Liébana-Cañada A.
    Nefrologia; 2013 Oct; 33(4):515-23. PubMed ID: 23897183
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy.
    Hasegawa M, Kondo F, Yamamoto K, Murakami K, Tomita M, Nabeshima K, Nakai S, Kato M, Ohashi A, Arai J, Hiki Y, Ishii J, Emi N, Sugiyama S, Yuzawa Y.
    Ther Apher Dial; 2010 Oct; 14(5):451-6. PubMed ID: 21175542
    [Abstract] [Full Text] [Related]

  • 5. The rationale and evidence base for the direct removal of serum-free light chains in the management of myeloma kidney.
    Cockwell P, Cook M.
    Adv Chronic Kidney Dis; 2012 Sep; 19(5):324-32. PubMed ID: 22920643
    [Abstract] [Full Text] [Related]

  • 6. Treatment of acute kidney injury with cast nephropathy.
    Walther C, Podoll AS, Finkel KW.
    Clin Nephrol; 2014 Jul; 82(1):1-6. PubMed ID: 24725380
    [Abstract] [Full Text] [Related]

  • 7. Impact of free light chain hemodialysis in myeloma cast nephropathy: a case-control study.
    Peters NO, Laurain E, Cridlig J, Hulin C, Cao-Huu T, Frimat L.
    Hemodial Int; 2011 Oct; 15(4):538-45. PubMed ID: 22111823
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study.
    Sens F, Chaintreuil D, Jolivot A, Guebre-Egziabher F, Robinson P, Karlin L, Bridoux F, Juillard L.
    Am J Nephrol; 2017 Oct; 46(5):355-363. PubMed ID: 29017155
    [Abstract] [Full Text] [Related]

  • 9. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies.
    Hutchison CA, Cockwell P, Reid S, Chandler K, Mead GP, Harrison J, Hattersley J, Evans ND, Chappell MJ, Cook M, Goehl H, Storr M, Bradwell AR.
    J Am Soc Nephrol; 2007 Mar; 18(3):886-95. PubMed ID: 17229909
    [Abstract] [Full Text] [Related]

  • 10. The role of immunological assessment in patients with acute kidney injury and possible myeloma.
    Lachmann HJ, Wassef NL.
    Adv Chronic Kidney Dis; 2012 Sep; 19(5):287-90. PubMed ID: 22920638
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Extracorporeal treatment of cast nephropathy.
    Gakhar B, Kobrin S, Berns JS.
    Semin Dial; 2011 Sep; 24(1):9-11. PubMed ID: 21324000
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Successful use of combined high cut-off haemodialysis and bortezomib for acute kidney injury associated with myeloma cast nephropathy.
    Ward F, Dunne O, Crotty TB, Fennelly D, Watson A, Holian J.
    Ir Med J; 2012 May; 105(5):148-9. PubMed ID: 22803494
    [Abstract] [Full Text] [Related]

  • 16. Extended high cut-off haemodialysis for myeloma cast nephropathy in Auckland, 2008-2012.
    Tan J, Lam-Po-Tang M, Hutchison CA, de Zoysa JR.
    Nephrology (Carlton); 2014 Jul; 19(7):432-5. PubMed ID: 24931113
    [Abstract] [Full Text] [Related]

  • 17. High cut-off hemodialysis and bortezomib-based therapy to rescue kidneys in myeloma-dependent cast nephropathy.
    Sinisalo M, Silvennoinen R, Wirta O.
    Am J Hematol; 2012 Jun; 87(6):640. PubMed ID: 22473521
    [Abstract] [Full Text] [Related]

  • 18. Recovery of kidney function following delayed use of Theralite™ dialyzer in a patient with myeloma cast nephropathy.
    Dahal K, Shastri S, Narayanasami U, Bijol V, Rider K, Strom JA, Jaber BL.
    Clin Nephrol; 2013 Apr; 79(4):318-22. PubMed ID: 22541683
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Paraprotein-Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy.
    Finkel KW, Cohen EP, Shirali A, Abudayyeh A, American Society of Nephrology Onco-Nephrology Forum.
    Clin J Am Soc Nephrol; 2016 Dec 07; 11(12):2273-2279. PubMed ID: 27526708
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.